Durect 
Welcome,         Profile    Billing    Logout  
 8 Products   266 Diseases  8 Products   3 Trials   3131 News 
6 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Posimir (bupivacaine CR) / Durect
2005-000538-19: Protocol CLIN004−0009 (February 02, 2005): A Pharmacodynamic/Pharmacokinetic Study of SABER−Bupivacaine and/or Bupivacaine HCl Administered Intra−operatively During Open Inguinal Hernia Repair under Local Anaesthesia

Ongoing
2
60
Europe
Saber™ Bupivacaine, Bupivacaine HCl 0.25 %,
DURECT Corporation
Inguinal hernia repair
 
 
Chronogesic (sufentanil) / Durect
ChiCTR2400089147: Study on the effective dose of cyclopofol combined with sufentanil for painless gastrointestinal endoscopy by age and gender factors

Not yet recruiting
4
300
 
The fixed dose of sufentanil was 0.1 μ g/kg, the initial dose of cyclopofol was 0.4 mg/kg, and the dose gradient was 0.05 mg/kg When MOAA/S is less than or equal to 1 min, the dose of cyclopofol in the next patient is determined according to whether gastroscopic implantation reaction occurs within 3 minutes of gastroscopic implantation. If no gastroscopic implantation reaction occurs in the patient, the dose gradient of cyclopofol in the next patient decreases by one dose gradient; If gastroscope implantation reaction occurs, a dose gradient is up-regulated; The fixed dose of sufentanil was 0.1 μ g/kg, the initial dose of cyclopofol was 0.4 mg/kg, and the dose gradient was 0.05 mg/kg When MOAA/S is less than or equal to 1 min, the dose of cyclopofol in the next patient is determined according to whether gastroscopic implantation reaction occurs within 3 minutes of gastroscopic implantation. If no gastroscopic implantation reaction occurs in the patient, the dose gradient of cyclopofol in the next patient decreases by one dose gradient; If gastroscope implantation reaction occurs, a dose gradient is up-regulated; The fixed dose of sufentanil was 0.1 μ g/kg, the initial dose of cyclopofol was 0.4 mg/kg, and the dose gradient was 0.05 mg/kg When MOAA/S is less than or equal to 1 min, the dose of cyclopofol in the next patient is determined according to whether gastroscopic implantation reaction occurs within 3 minutes of gastroscopic implantation. If no gastroscopic implantation reaction occurs in the patient, the dose gradient of cyclopofol in the next patient decreases by one dose gradient; If gastroscope implantation reaction occurs, a dose gradient is up-regulated; The fixed dose of sufentanil was 0.1 μ g/kg, the initial dose of cyclopofol was 0.4 mg/kg, and the dose gradient was 0.05 mg/kg When MOAA/S is less than or equal to 1 min, the dose of cyclopofol in the next patient is determined according to whether gastroscopic implantation reaction occurs within 3 minutes of gastroscopic implantation. If no gastroscopic implantation reaction occurs in the patient, the dose gradient of cyclopofol in the next patient decreases by one dose gradient; If gastroscope implantation reaction occurs, a dose gradient is up-regulated; The fixed dose of sufentanil was 0.1 μ g/kg, the initial dose of cyclopofol was 0.4 mg/kg, and the dose gradient was 0.05 mg/kg When MOAA/S is less than or equal to 1 min, the dose of cyclopofol in the next patient is determined according to whether gastroscopic implantation reaction occurs within 3 minutes of gastroscopic implantation. If no gastroscopic implantation reaction occurs in the patient, the dose gradient of cyclopofol in the next patient decreases by one dose gradient; If gastroscope implantation reaction occurs, a dose gradient is up-regulated; The fixed dose of sufentanil was 0.1 μ g/kg, the initial dose of cyclopofol was 0.4 mg/kg, and the dose gradient was 0.05 mg/kg When MOAA/S is less than or equal to 1 min, the dose of cyclopofol in the next patient is determined according to whether gastroscopic implantation reaction occurs within 3 minutes of gastroscopic implantation. If no gastroscopic implantation reaction occurs in the patient, the dose gradient of cyclopofol in the next patient decreases by one dose gradient; If gastroscope implantation reaction occurs, a dose gradient is up-regulated
Huludao Central Hospital; Huludao Central Hospital, Self-funding
Painless gastrointestinal endoscopy
 
 
ChiCTR2400087333: Effective dose of remazolam in inhibiting laryngeal mask implantation in children when combined with sufentanil

Recruiting
4
120
 
Using the modified sequential method, the initial dose of remazolam was set at 0.30mg/kg according to the pre-test results and related studies. If the larynx mask implantation reaction was positive, the dose of remazolam was increased by 0.01 mg/kg in the next patient; if the larynx mask implantation reaction was negative, the dose of remazolam was decreased by 0.01 mg/kg in the next patient. For the first negative reaction, the formal test began until the alternating wave of positive and negative reaction formed 7 inflection points to end the test.; Using the modified sequential method, the initial dose of remazolam was set at 0.30mg/kg according to the pre-test results and related studies. If the larynx mask implantation reaction was positive, the dose of remazolam was increased by 0.01 mg/kg in the next patient; if the larynx mask implantation reaction was negative, the dose of remazolam was decreased by 0.01 mg/kg in the next patient. For the first negative reaction, the formal test began until the alternating wave of positive and negative reaction formed 7 inflection points to end the test.; Using the modified sequential method, the initial dose of remazolam was set at 0.30mg/kg according to the pre-test results and related studies. If the larynx mask implantation reaction was positive, the dose of remazolam was increased by 0.01 mg/kg in the next patient; if the larynx mask implantation reaction was negative, the dose of remazolam was decreased by 0.01 mg/kg in the next patient. For the first negative reaction, the formal test began until the alternating wave of positive and negative reaction formed 7 inflection points to end the test.
Shanghai Children's Hospital; Shanghai Children‘s Hospital, Discipline construction funds
Children undergoing laryngeal mask anesthesia
 
 
DUR-928 / Durect
AHFIRM, NCT04563026: A Phase 2b Study in Subjects With Alcoholic Hepatitis to Evaluate Safety and Efficacy of DUR-928 Treatment

Completed
2
307
Europe, US, RoW
DUR-928 30 mg, DUR-928 90 mg, Placebo+ Standard of Care (SOC)
Durect, CTI Clinical Trial and Consulting Services
Alcoholic Hepatitis
09/23
09/23
2020-004534-38: A Phase 2b Study in Subjects With Alcoholic Hepatitis to Evaluate Safety and Efficacy of DUR-928 Treatment

Not yet recruiting
2
300
Europe
DUR-928 30mg, DUR-928 90mg, Methylprednisolone, DUR-928, NDC 59762-0051-1, Concentrate for solution for infusion, Capsule, hard + tablet, Methylprednisolone
DURECT Corporation, DURECT Corporation
Alcoholic hepatitis, Damage to your liver due to drinking too much alcohol over a long period of time, Diseases [C] - Nutritional and Metabolic Diseases [C18]
 
 
DUR-928/AH, NCT03917407: DUR-928 in Patients With Alcoholic Hepatitis

Completed
2
43
US
DUR-928 (Moderate AH), Sulfated oxysterol: 5 cholesten-3β, 25-diol 3-sulfate (25HC3S), DUR-928 (Severe AH)
Craig James McClain, National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Alcoholic Hepatitis
09/23
09/23
ORADUR-hydromorphone / Durect, Cassava
No trials found
ORADUR-oxymorphone / Durect, Cassava
No trials found
ORADUR-hydrocodone / Durect
No trials found
sustained-release ophthalmology product / Santen
No trials found

Download Options